Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA lifts partial clinical hold on head and neck cancer trials of durvalumab

Nov. 22, 2016

FDA approves Darzalex in combination with standard of care for relapsed multiple myeloma

Nov. 22, 2016

Rosetta Genomics enters research agreement with Sheba Medical Center

Nov. 22, 2016

FDA lifts partial clinical hold on trials evaluating Aduro Biotech's LADD platform

Nov. 22, 2016

Bristol-Myers Squibb launches elotuzumab in Japan

Nov. 21, 2016

UMC launches phase II program combining DCVax-L and pembrolizumab

Nov. 21, 2016

CD40L-encoding adenovirus enhances dendritic cell therapy for cancer

Nov. 17, 2016

Pfizer initiates phase I trial of PF-06747143 in AML

Nov. 17, 2016

Genexine signs agreement with Merck & Co.

Nov. 17, 2016

Sorrento's TNK Therapeutics signs binding term sheet to acquire Virttu Biologics

Nov. 17, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.